PHARMACOKINETICS OF RIFABUTIN IN COMBINATION WITH LOPINAVIR-RITONAVIR IN ADULT PATIENTS WITH HIV AND TUBERCULOSIS CO-INFECTION IN BURKINA FASO. (12th February 2017)

• Record Type: Journal Article
• Authors: Ouedraogo, Henri Gautier; Matteelli, Alberto; Regazzi, Mario; Tarnagda, Grissoum; Villani, Paola; Sulis, Giorgia; Diagbouga, Serge; Roggi, Alberto; Giorgetti, Francesco; Kouanda, Seni
• Is Part Of: BMJ global health. Volume 2(2017)Supplement 2
• Page Start: A38
• Page End: A38
• Publication Date: 2017-02-12
• Subjects: World health -- Periodicals; 362.105
• DOI: 10.1136/bmjgh-2016-000260.100
• Languages: English
• ISSNs: 2059-7908

Abstract

Abstract : Background: This study aimed to assess the pharmacokinetic profile of rifabutin (RBT) given at 150 mg or 300 mg every other day (EOD) in tuberculosis (TB)-HIV co-infected adult patients. Methods: This is a pharmacokinetic prospective, pilot, open, randomised study of two doses of RBT in combination with lopinavir/ritonavir among HIV−TB patients in Burkina. Sixteen patients were randomised in two arms: TB treatment consisting HZE standard doses in association with RBT150 mg EOD (arm A, 8 patients) or RBT300 mg EOD (arm B, 8 patients) in combination with lopinavir/ritonavir. RBT plasma concentrations were evaluated after two weeks of combined HIV and TB treatment. Samples were collected at pre-dosing and at 1, 2, 3, 4, 6, 8 and12 hours after drug ingestion to measure plasma drug concentration using HPLC–MS/MS assay. Results: The mean Cmax and AUC in the RBT 150 mg arm (Cmax=0.35±0, 18 µg/mL, AUC(0–24)=3.94±2, 1 µg.h/mL) were significantly lower (p=0.01) than those of the RBT 300 mg arm (Cmax=0.75±0.54 µg/mL AUC(0–24)=7.1±2.7 µg.h/mL). There was no significant difference in Tmax (Tmax=3.44±2.01 hours vs Tmax=3.86±2.04 hours) p=0.687. RBT follows linear kinetics and no significant differences were apparent in the mean oral clearance (CL/F) estimates (p=0.683), which were dose independent and similar for the 2 assessment doses. Five of 8 patients in RBT150 mg arm had a Cmax below plasma therapeutic limit (<0.3 µg/ml). All patients in RBT 300 mg arm had a higher Cmax than this limit. Also, at 48 hours of drug ingestion, all patients in the RBT 300 mg arm (8/8) had a mycobacterial minimum inhibitory concentration (MIC) above the limit (>0.06 µg/mL) compared with 4 of 8 patients in the RBT150 mg arm. The means Cmax, AUC (0–24) and Tmax of 25-O-desacetyl rifabutin of the RBT 300 mg arm were increased by 100% and 50% respectively compared to the RBT150 mg arm. Conclusions: This study confirmed that the dose of rifabutin 150 mg three times a week in combination with lopinavir/ ritonavir is inadequate and could lead to the selection of rifamycin-resistant mycobacteria.